FITsOnTheGo (@fitsonthego) 's Twitter Profile
FITsOnTheGo

@fitsonthego

#FITsOnTheGo account for media related to cardiovascular education for Fellows In Training. Associated with @MayoCVFellows, @ACCinTouch, and #ACCFIT

ID: 1510326398749184013

linkhttp://www.youtube.com/fitsonthego calendar_today02-04-2022 18:41:00

201 Tweet

361 Followers

287 Following

Norma Nicole Gamarra Valverde (@gamarra_nn) 's Twitter Profile Photo

FIT Jeopardy is one of those activities you can’t miss at ACC conference. The spirit of competition, learning, and camaraderie among the fellows is truly inspiring. Today, I had the privilege of interviewing the heart and mind behind this project, Dr. Saurabh S Dani, MD, MSc, for

FIT Jeopardy is one of those activities you can’t miss at ACC conference. The spirit of competition, learning, and camaraderie among the fellows is truly inspiring. Today, I had the privilege of interviewing the heart and mind behind this project, Dr. <a href="/SaurabhSDani/">Saurabh S Dani, MD, MSc</a>, for
FITsOnTheGo (@fitsonthego) 's Twitter Profile Photo

Lorundrostat—a new player in hypertension management? This aldosterone synthase inhibitor showed promising efficacy in patients with uncontrolled hypertension despite a standardized regimen. We covered it at #ACC25—don’t miss the science. Luke J. Laffin Cleveland Clinic Jagroop Doad

FITsOnTheGo (@fitsonthego) 's Twitter Profile Photo

Full circle at #ACC25! We caught up with Dr. Jeffrey Geske, MD, one of the original founders (alongside Dr. Michael Cullen) of FITsOnTheGo An inspiring convo on how the initiative started—and how YOU can get involved in #MedEd Shoutout to Mayo Clinic Rochester Cardiology Fellows for keeping the spirit alive

FITsOnTheGo (@fitsonthego) 's Twitter Profile Photo

Clopidogrel vs Aspirin for long-term monotherapy after PCI in high ischemic risk patients? Big implications for long-term care. Full interview now on YouTube | FITsOnTheGo 삼성서울병원 Sanjana Nagraj #ACC25 Mayo Clinic CV

FITsOnTheGo (@fitsonthego) 's Twitter Profile Photo

The ALPACA Phase 2 trial studied Lepodisiran, a small-interfering RNA, with results extending out to 540 days. Extended durability, promising reductions. We had the absolute pleasure to talk with Dr Nissen from Cleveland Clinic at #ACC25 Mohammad A. Hossain RutgersIMRes

FITsOnTheGo (@fitsonthego) 's Twitter Profile Photo

5-year outcomes are in! At #ACC25, we caught up with Dr. Michael Reardon to discuss the Evolut Low-Risk TAVR vs SAVR trial. What does the long-term data reveal about mortality and stroke in low-risk patients? Houston Methodist CV Mohanad Hamandi, MD Mayo Clinic CV Mayo Clinic Rochester Cardiology Fellows

FITsOnTheGo (@fitsonthego) 's Twitter Profile Photo

Dr. Michael Reardon, TAVI pioneer Houston Methodist CV, sat down with Mohanad Hamandi Mayo Clinic CV Mohanad Hamandi, MD to discuss the Evolut 5-Year Outcomes After Transcatheter or Surgical Aortic Valve Replacement in Low-Risk Patients With Aortic Stenosis. #ACC25